Incyte Tosses IO Candidates To Focus On High-Value Pipeline Assets
The drug maker’s next-generation JAK1 inhibitor povorcitinib has an addressable market potentially worth more than $3bn if it wins approval in hidradenitis suppurativa and vitiligo.

The drug maker’s next-generation JAK1 inhibitor povorcitinib has an addressable market potentially worth more than $3bn if it wins approval in hidradenitis suppurativa and vitiligo.